BG103915A - Sertraline salts and sertralin-containing batched forms with delayed release - Google Patents

Sertraline salts and sertralin-containing batched forms with delayed release

Info

Publication number: BG103915A
Authority: BG; Bulgaria
Prior art keywords: sertraline; forms; batched; sertralin; delayed release
Prior art date: 1997-07-01

Application number

BG103915A

Other languages

Bulgarian (bg)

English (en)

Inventor

Ende Mary Am

William Curatolo

Hylar Friedman

Ravi Shanker

Scott HERBIG

Dwayne Friesen

James West

Original Assignee

Pfizer Inc.

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1997-07-01

Filing date

1999-11-23

Publication date

2000-07-31

1999-11-23 Application filed by Pfizer Inc. filed Critical Pfizer Inc.

2000-07-31 Publication of BG103915A publication Critical patent/BG103915A/xx

Links

VGKDLMBJGBXTGI-SJCJKPOMSA-N sertraline Chemical class C1([C@@H]2CC[C@@H](C3=CC=CC=C32)NC)=CC=C(Cl)C(Cl)=C1 VGKDLMBJGBXTGI-SJCJKPOMSA-N 0.000 title abstract 8
230000003111 delayed effect Effects 0.000 title 1
229960002073 sertraline Drugs 0.000 abstract 7
CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 abstract 2
JVTAAEKCZFNVCJ-REOHCLBHSA-N L-lactic acid Chemical compound C[C@H](O)C(O)=O JVTAAEKCZFNVCJ-REOHCLBHSA-N 0.000 abstract 2
229940116871 l-lactate Drugs 0.000 abstract 2
238000000034 method Methods 0.000 abstract 2
QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 abstract 1
159000000021 acetate salts Chemical class 0.000 abstract 1
201000010099 disease Diseases 0.000 abstract 1
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
150000003839 salts Chemical class 0.000 abstract 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
- A61K9/0004—Osmotic delivery systems; Sustained release driven by osmosis, thermal energy or gas
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2009—Inorganic compounds
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2886—Dragees; Coated pills or tablets, e.g. with film or compression coating having two or more different drug-free coatings; Tablets of the type inert core-drug layer-inactive layer
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5005—Wall or coating material
- A61K9/5021—Organic macromolecular compounds
- A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
- A61K9/5042—Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose
- A61K9/5047—Cellulose ethers containing no ester groups, e.g. hydroxypropyl methylcellulose

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Animal Behavior & Ethology (AREA)
Veterinary Medicine (AREA)
Medicinal Chemistry (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Chemical Kinetics & Catalysis (AREA)
Organic Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Epidemiology (AREA)
Neurosurgery (AREA)
Biomedical Technology (AREA)
Neurology (AREA)
Psychiatry (AREA)
Hematology (AREA)
Obesity (AREA)
Immunology (AREA)
Child & Adolescent Psychology (AREA)
Pain & Pain Management (AREA)
Diabetes (AREA)
Addiction (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Medicinal Preparation (AREA)
Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

BG103915A 1997-07-01 1999-11-23 Sertraline salts and sertralin-containing batched forms with delayed release BG103915A (en)

Applications Claiming Priority (5)

Application Number	Priority Date	Filing Date	Title
US5149897P	1997-07-01	1997-07-01
US5141497P	1997-07-01	1997-07-01
US5142097P	1997-07-01	1997-07-01
US5140297P	1997-07-01	1997-07-01
PCT/IB1998/000934 WO1999001121A1 (fr)	1997-07-01	1998-06-15	Sels de sertraline et formes posologiques de sertraline, a liberation prolongee

Publications (1)

Publication Number	Publication Date
BG103915A true BG103915A (en)	2000-07-31

Family

ID=27489408

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
BG103915A BG103915A (en)	1997-07-01	1999-11-23	Sertraline salts and sertralin-containing batched forms with delayed release

Country Status (32)

Country	Link
US (1)	US6517866B1 (fr)
EP (1)	EP0999830A1 (fr)
JP (1)	JP2000514101A (fr)
KR (2)	KR100446366B1 (fr)
CN (1)	CN1256085C (fr)
AP (1)	AP1526A (fr)
AR (2)	AR015919A1 (fr)
AU (1)	AU739261B2 (fr)
BG (1)	BG103915A (fr)
BR (1)	BR9810403A (fr)
CA (1)	CA2290966C (fr)
CO (1)	CO4940402A1 (fr)
DZ (1)	DZ2546A1 (fr)
EA (1)	EA002482B1 (fr)
HR (1)	HRP980379B1 (fr)
HU (1)	HUP0002296A3 (fr)
ID (1)	ID23503A (fr)
IL (2)	IL152330A0 (fr)
IS (1)	IS5265A (fr)
MY (1)	MY129175A (fr)
NO (1)	NO996518L (fr)
NZ (2)	NZ501251A (fr)
OA (1)	OA11245A (fr)
PA (1)	PA8454401A1 (fr)
PE (1)	PE88699A1 (fr)
PL (1)	PL337806A1 (fr)
SK (1)	SK180499A3 (fr)
TN (1)	TNSN98125A1 (fr)
TR (1)	TR199903280T2 (fr)
TW (1)	TWI241188B (fr)
UY (1)	UY25067A1 (fr)
WO (1)	WO1999001121A1 (fr)

Families Citing this family (70)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US20040208926A1 (en) *	1997-07-01	2004-10-21	Pfizer Inc	Solubilized sertraline compositions
JP4533531B2 (ja) *	1998-04-03	2010-09-01	ビーエムリサーチエイ／エス	制御放出組成物
US6706283B1 (en) *	1999-02-10	2004-03-16	Pfizer Inc	Controlled release by extrusion of solid amorphous dispersions of drugs
ES2290027T3 (es) *	1999-05-20	2008-02-16	Elan Corporation, Plc	Formulaciones multiparticuladas y de liberacion controlada de inhibidores selectivos de la recaptacion de serotonina.
IE990406A1 (en)	1999-05-20	2000-12-27	Elan Corp Plc	Multiparticulate controlled release selective serotonin reuptake inhibitor formulations.
EP1671628B1 (fr) *	1999-09-03	2012-10-03	APBI Holdings, LLC	Inhibiteurs de réabsorption de sérotonine à action rapide pour le traitement des dysfonctions sexuelles
GB9923045D0 (en) *	1999-09-29	1999-12-01	Novartis Ag	New oral formulations
JP2003518487A (ja) *	1999-12-23	2003-06-10	ファイザー・プロダクツ・インク	ヒドロゲル駆動型積層薬物製剤
US6620431B1 (en) *	2000-04-17	2003-09-16	Charles Signorino	Shellac film coatings providing release at selected pH and method
US20030086972A1 (en) *	2000-08-09	2003-05-08	Appel Leah E.	Hydrogel-driven drug dosage form
BR0113626A (pt)	2000-08-30	2003-06-17	Pfizer Prod Inc	Formulações de liberação sustentada para secretores de hormÈnio do crescimento
US6482440B2 (en) *	2000-09-21	2002-11-19	Phase 2 Discovery, Inc.	Long acting antidepressant microparticles
SE0004671D0 (sv)	2000-12-15	2000-12-15	Amarin Dev Ab	Pharmaceutical formulation
JP2002212062A (ja) *	2001-01-24	2002-07-31	Teijin Ltd	遅延放出制御組成物
CN1204922C (zh) *	2001-02-15	2005-06-08	株式会社三和化学研究所	新的眼科用组合物
AU2002248792B2 (en) *	2001-04-18	2006-09-21	Nostrum Pharmaceuticals Inc.	A novel coating for a sustained release pharmaceutical composition
AU2002316020B2 (en) *	2001-07-16	2007-03-15	Astrazeneca Ab	Pharmaceutical formulation comprising a proton pump inhibitor and antacids
EP1429744A1 (fr) *	2001-09-21	2004-06-23	Egalet A/S	Systeme a liberation de polymere de morphine
US20040234602A1 (en)	2001-09-21	2004-11-25	Gina Fischer	Polymer release system
NZ532096A (en) *	2001-09-28	2006-10-27	Mcneil Ppc Inc	Dosage forms having an inner core and outer shell with different shapes
US7005138B2 (en) *	2001-12-21	2006-02-28	Duramed Pharmaceuticals, Inc.	Method of systematically delivering SSRIs
US7670612B2 (en) *	2002-04-10	2010-03-02	Innercap Technologies, Inc.	Multi-phase, multi-compartment capsular delivery apparatus and methods for using same
US20100189797A1 (en)	2002-06-10	2010-07-29	Julien Mendlewicz	Oral antidepressant formulation
US20050226926A1 (en) *	2002-07-25	2005-10-13	Pfizer Inc	Sustained-release tablet composition of pramipexole
WO2004024130A2 (fr) *	2002-09-16	2004-03-25	Sepracor, Inc.	Traitement de troubles du snc par trans 4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-n-methyl-1-napthalenamine
US20040220153A1 (en) *	2002-09-24	2004-11-04	Jost-Price Edward Roydon	Methods and reagents for the treatment of diseases and disorders associated with increased levels of proinflammatory cytokines
CA2415154C (fr) *	2002-12-24	2009-06-16	Biovail Laboratories Inc.	Preparations a liberation modifiee contenant des inhibiteurs selectifs de la recapture de la serotonine
WO2004065348A1 (fr)	2003-01-23	2004-08-05	Pfizer Products Inc.	Sels pharmaceutiquement acceptables de sertraline et compositions pharmaceutiques correspondantes
TW200509958A (en) *	2003-02-14	2005-03-16	Combinatorx Inc	Methods and reagents for the treatment of diseases and disorders associated with increased levels of proinflammatory cytokines
WO2004084868A1 (fr)	2003-03-26	2004-10-07	Egalet A/S	Systeme de liberation regulee de morphine
MXPA05010636A (es) *	2003-04-04	2005-12-12	Pharmacia Corp	Comprimidos de multiparticulas preparados por compresion de liberacion oral prolongada.
KR101192722B1 (ko)	2003-04-24	2012-10-18	자고텍 아게	정해진 핵 위치를 가지는 서방성 정제
WO2005000786A1 (fr) *	2003-05-23	2005-01-06	Transform Pharmaceuticals, Inc.	Compositions de sertraline
WO2005016318A1 (fr) *	2003-08-08	2005-02-24	Biovail Laboratories Inc.	Comprime d'hydrochlorure de bupropion a liberation modifiee
JP4791970B2 (ja) *	2003-11-04	2011-10-12	シプラ・リミテッド	選択的セロトニン再取込み阻害剤の多形体の製造方法
PE20060003A1 (es) *	2004-03-12	2006-03-01	Smithkline Beecham Plc	Formulacion farmaceutica polimerica para moldear por inyeccion
KR100772980B1 (ko) *	2004-04-01	2007-11-02	한미약품 주식회사	메트포르민의 경구투여용 서방성 제제
US20050232911A1 (en) *	2004-04-19	2005-10-20	Schreiber Brian D	Prevention and treatment of metabolic abnormalities associated with excess intramyocellular lipid
ITMI20041295A1 (it) *	2004-06-25	2004-09-25	Cosmo Spa	Composizioni farmaceutiche antimicrobiche orali
UA93608C2 (ru)	2004-08-13	2011-02-25	Берингер Ингельхайм Интернациональ Гмбх	композициЯ таблетки пролонгированного высвобождения, которая содержит прамипексол или его фармацевтически приемлемую соль, СПОСОБ EE ИЗГОТОВЛЕНИЯ И EE ПРИМЕНЕНИЕ
KR100920856B1 (ko) *	2004-11-30	2009-10-09	(주)아모레퍼시픽	선택적 세로토닌 재흡수 억제제의 연장방출 제제 및 그제조방법
WO2006072878A1 (fr) *	2005-01-07	2006-07-13	Ranbaxy Laboratories Limited	Formes posologiques orales de sertraline possedant une taille de particule controlee, et leurs procedes de preparation
US20080274183A1 (en) *	2005-02-04	2008-11-06	Phillip Michael Cook	Thermoplastic articles containing a medicament
US20080213381A1 (en) *	2005-03-14	2008-09-04	Pharmaceutical Industries Limited	Oral Drug Delivery System
CA2611081C (fr) *	2005-06-03	2016-05-31	Egalet A/S	Systeme d'administration de medicaments permettant d'administrer des substances actives dispersees dans un milieu de dispersion
US8747897B2 (en) *	2006-04-27	2014-06-10	Supernus Pharmaceuticals, Inc.	Osmotic drug delivery system
US7893053B2 (en) *	2006-06-16	2011-02-22	Theracos, Inc.	Treating psychological conditions using muscarinic receptor M1 antagonists
SI2049123T1 (sl)	2006-08-03	2013-04-30	Horizon Pharma Ag	Zdravljenje revmatoznih bolezni z zadrĹľanim sproĹˇÄŤanjem glukokortikoida
NZ577560A (en) *	2007-01-16	2012-01-12	Egalet Ltd	Use of i) a polyglycol and ii) an active drug substance for the preparation of a pharmaceutical composition for i) mitigating the risk of alcohol induced dose dumping and/or ii) reducing the risk of drug abuse
EP2155167A2 (fr)	2007-06-04	2010-02-24	Egalet A/S	Compositions pharmaceutiques à libération contrôlée pour un effet prolongé
WO2009034431A2 (fr)	2007-09-10	2009-03-19	Pfizer Inc.	Formes posologiques à libération contrôlée de la varenicline
US20110142905A1 (en) *	2008-08-14	2011-06-16	Bioneer A/S	Coated tablets with remaining degradation surface over the time
DE102008051572A1 (de)	2008-09-05	2010-03-11	Maria Clementine Martin Klosterfrau Vertriebsgesellschaft Mbh	Herstellung von Phosphatbindern und auf diese Weise hergestellte Phosphatbinder
AU2008243202B2 (en) *	2008-11-11	2015-08-20	Cosmo Technologies Ltd	Oral antimicrobial pharmaceutical compositions
NZ594207A (en)	2009-02-06	2013-03-28	Egalet Ltd	Immediate release composition resistant to abuse by intake of alcohol
NZ597283A (en)	2009-06-24	2013-07-26	Egalet Ltd	Controlled release formulations
CN102695501A (zh)	2009-11-09	2012-09-26	聚光灯技术合伙有限责任公司	碎裂水凝胶
CN106913902A (zh)	2009-11-09	2017-07-04	聚光灯技术合伙有限责任公司	多糖基水凝胶
BR112015000150A2 (pt)	2012-07-06	2017-06-27	Egalet Ltd	composições farmacêuticas dissuasoras de abuso de liberação controlada
JP6041823B2 (ja)	2013-03-16	2016-12-14	ファイザー・インク	トファシチニブの経口持続放出剤形
WO2016020936A2 (fr) *	2014-07-21	2016-02-11	Patel Jayendrakumar Dasharathlal	Nouvelle forme posologique pharmaceutique orale de rétention gastrique
CN104402705B (zh) *	2014-11-04	2017-04-12	成都理工大学	球形柠檬酸钙及其制备方法和应用
JP6455293B2 (ja) *	2015-04-21	2019-01-23	ニプロ株式会社	セルトラリン及び／又はその薬学上許容しうる塩を含む製剤
EA201992116A1 (ru) *	2017-03-08	2020-01-29	СИНРКС ФАРМА, ЭлЭлСи	Фармацевтические составы флороглюцинола и триметилфлороглюцинола
KR102745548B1 (ko) *	2017-10-05	2024-12-23	푸락 바이오켐 비.브이.	락테이트 분말 및 이의 제조방법
CN109432038A (zh) *	2018-12-28	2019-03-08	乐普制药科技有限公司	一种含有盐酸舍曲林的肠溶片剂及其制备方法
GB201914779D0 (en) *	2019-10-11	2019-11-27	Oxford Medical Products Ltd	Polymer compositions
EP4311113B1 (fr)	2022-07-21	2026-04-08	Rohde & Schwarz GmbH & Co. KG	Récepteur de fréquence radio et son procédé de fonctionnement
CN118522388B (zh) *	2024-07-25	2024-10-11	北京科技大学	二元复配有机缓蚀剂优化方法、装置、设备及介质
CN119915068B (zh) *	2025-04-01	2025-07-08	烟台华孚制冷设备有限公司	一种盘式制冷装置及冰淇淋机

Family Cites Families (44)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4536518A (en)	1979-11-01	1985-08-20	Pfizer Inc.	Antidepressant derivatives of cis-4-phenyl-1,2,3,4-tetrahydro-1-naphthalenamine
DK150008C (da)	1981-11-20	1987-05-25	Benzon As Alfred	Fremgangsmaade til fremstilling af et farmaceutisk oralt polydepotpraeparat
US5112619A (en)	1985-11-12	1992-05-12	Eli Lilly And Company	Orally administerable sustained release pharmaceutical formulation
US4797286A (en)	1985-11-12	1989-01-10	Eli Lilly And Company	Orally administerable sustained release pharmaceutical formulations
US4847092A (en)	1985-11-12	1989-07-11	Eli Lilly And Company	Orally administerable sustained release pharmaceutical formulations
US4803076A (en) *	1986-09-04	1989-02-07	Pfizer Inc.	Controlled release device for an active substance
DE3700420A1 (de)	1986-12-22	1988-07-07	Efka Werke Kiehn Gmbh Fritz	Tabakerzeugnis fuer die selbstverfertigung einer zigarette, insbesondere filter-zigarette
US5135947A (en)	1987-04-09	1992-08-04	Eli Lilly And Company	1-phenyl-3-naphthalenyloxypropanamines and their use as selective serotonin reuptake inhibitors
US4777288A (en)	1987-06-11	1988-10-11	Pfizer Inc.	Process for preparing a 4,4-diphenylbutanoic acid derivative
US4792448A (en)	1987-06-11	1988-12-20	Pfizer Inc.	Generic zero order controlled drug delivery system
US4839104A (en)	1987-06-11	1989-06-13	Pfizer, Inc.	Process for preparing sertraline intermediates
US4971998A (en)	1987-10-22	1990-11-20	Massachusetts Institute Of Technology	Methods for treating the premenstrual or late luteal phase syndrome
US4876282A (en)	1987-11-25	1989-10-24	Eli Lilly And Company	1-Phenylalkylamines as selective serotonin uptake inhibitors
US4855500A (en)	1988-05-04	1989-08-08	Pfizer Inc.	Process for preparing a ketimine
US5026707A (en)	1988-05-23	1991-06-25	Eli Lilly And Company	Ring-substituted 2-amino-1,2,3,4-tetrahydronaphthalenes
IL91398A (en) *	1988-08-30	1994-05-30	Pfizer	Pharmaceutical delivery device comprising active substance surrounded by asymmetric membrane
IL114715A (en)	1989-02-27	1997-01-10	Lilly Co Eli	Intermediate compounds for ring-substituted 2-amino-1, 2, 3, 4-tetrahydronaphthalenes and 3-aminochromanes
US4981870A (en)	1989-03-07	1991-01-01	Pfizer Inc.	Use of 4-phenyl-1,2,3,4-tetrahydro-1-naphthalenamine derivatives in the treatment of psychosis, inflammation and as immunosuppressants
US4983401A (en)	1989-05-22	1991-01-08	Kinaform Technology, Inc.	Sustained release pharmaceutical preparations having pH controlled membrane coatings
ATE96999T1 (de)	1989-08-30	1993-11-15	Pfizer	Verwendung von sertralin zur behandlung von abhaengigkeiten von chemischen stoffen.
US4940731A (en)	1989-08-30	1990-07-10	Pfizer Inc.	Method of treating premature ejaculation using sertraline
US5130338A (en)	1989-08-30	1992-07-14	Pfizer Inc.	Method of treating chemical dependencies using sertraline
US4962128A (en) *	1989-11-02	1990-10-09	Pfizer Inc.	Method of treating anxiety-related disorders using sertraline
AU8072691A (en)	1990-06-28	1992-01-23	Beecham Group Plc	Pharmaceutical preparations
ATE118345T1 (de)	1990-08-07	1995-03-15	Pfizer	Verwendung von interfacial polymerisierten membranen in abgabevorrichtungen.
WO1992002215A1 (fr)	1990-08-09	1992-02-20	Massachusetts Institute Of Technology	Methodes servant a traiter le syndrome premenstruel ou le syndrome de l'insuffisance luteale
US5104899A (en)	1990-08-13	1992-04-14	Sepracor, Inc.	Methods and compositions for treating depression using optically pure fluoxetine
AU658155B2 (en)	1990-11-24	1995-04-06	Beecham Group Plc	Use of paroxetine for the treatment of senile dementia, or anorexia
ES2153071T3 (es)	1991-02-08	2001-02-16	Lilly Co Eli	2-amino-1,2,3,4-tetrahidronaftalenos y 3-aminocromanos sustituidos en anillo.
WO1992018005A1 (fr)	1991-04-16	1992-10-29	National Institutes Of Health	Procede de traitement de la trichotillomanie et de l'onychophagie
US5196607A (en)	1992-02-14	1993-03-23	Pfizer Inc.	Process for preparing ketone enantiomer
ES2124303T3 (es)	1992-03-25	1999-02-01	Depomed Inc	Formas de dosificacion de farmacos orales de liberacion retardada a base de hidroxietilcelulosa.
US5518730A (en)	1992-06-03	1996-05-21	Fuisz Technologies Ltd.	Biodegradable controlled release flash flow melt-spun delivery system
US5248699A (en)	1992-08-13	1993-09-28	Pfizer Inc.	Sertraline polymorph
US6440457B1 (en)	1993-05-27	2002-08-27	Alza Corporation	Method of administering antidepressant dosage form
IE930485A1 (en)	1993-06-28	1994-12-28	Hemisphere Ltd	Antidepressant agents with a rapid onset of action
US5597826A (en)	1994-09-14	1997-01-28	Pfizer Inc.	Compositions containing sertraline and a 5-HT1D receptor agonist or antagonist
ATE214276T1 (de)	1994-09-19	2002-03-15	Du Pont Pharm Co	Zusammensetzungen von opioid antagonisten mit selektiven serotonin-aufnahme inhibitoren, zur behandlung von alkoholismus und alkohoabhängigkeit
ATE235237T1 (de)	1995-07-17	2003-04-15	Pfizer	Sertralin zur behandlung von post-myocard-infarkt-patienten
GB9514842D0 (en)	1995-07-20	1995-09-20	Smithkline Beecham Plc	Novel formulation
UA48219C2 (uk)	1996-03-25	2002-08-15	Елі Ліллі Енд Компані	Композиція для вгамування болю (варіанти) та спосіб вгамування болю
ZA97976B (en) *	1996-04-05	1997-08-18	Alza Corp	Uniform drug delivery theraphy.
US5741807A (en)	1996-09-27	1998-04-21	Cytos Pharmaceuticals, L.P.	Histidine compositions and methods for treating or preventing infectious and non-infectious diarrheas
US6590083B1 (en)	1999-04-16	2003-07-08	Ortho-Mcneil Pharmaceutical, Inc.	Ketolide antibacterials

1998
- 1998-06-15 CA CA002290966A patent/CA2290966C/fr not_active Expired - Fee Related
- 1998-06-15 IL IL15233098A patent/IL152330A0/xx unknown
- 1998-06-15 BR BR9810403-9A patent/BR9810403A/pt not_active Application Discontinuation
- 1998-06-15 NZ NZ501251A patent/NZ501251A/en unknown
- 1998-06-15 HU HU0002296A patent/HUP0002296A3/hu unknown
- 1998-06-15 KR KR10-2003-7002633A patent/KR100446366B1/ko not_active Expired - Fee Related
- 1998-06-15 CN CNB988066963A patent/CN1256085C/zh not_active Expired - Fee Related
- 1998-06-15 TR TR1999/03280T patent/TR199903280T2/xx unknown
- 1998-06-15 AU AU75449/98A patent/AU739261B2/en not_active Ceased
- 1998-06-15 SK SK1804-99A patent/SK180499A3/sk unknown
- 1998-06-15 NZ NZ513456A patent/NZ513456A/xx unknown
- 1998-06-15 EA EA199900964A patent/EA002482B1/ru not_active IP Right Cessation
- 1998-06-15 EP EP98923020A patent/EP0999830A1/fr not_active Withdrawn
- 1998-06-15 WO PCT/IB1998/000934 patent/WO1999001121A1/fr not_active Ceased
- 1998-06-15 US US09/380,897 patent/US6517866B1/en not_active Expired - Fee Related
- 1998-06-15 IL IL13308098A patent/IL133080A0/xx unknown
- 1998-06-15 JP JP11506775A patent/JP2000514101A/ja active Pending
- 1998-06-15 PL PL98337806A patent/PL337806A1/xx unknown
- 1998-06-15 ID IDW991704A patent/ID23503A/id unknown
- 1998-06-15 KR KR10-1999-7012073A patent/KR100412327B1/ko not_active Expired - Fee Related
- 1998-06-25 AP APAP/P/1998/001281A patent/AP1526A/en active
- 1998-06-25 TW TW087110253A patent/TWI241188B/zh not_active IP Right Cessation
- 1998-06-26 PE PE1998000572A patent/PE88699A1/es not_active Application Discontinuation
- 1998-06-29 UY UY25067A patent/UY25067A1/es not_active IP Right Cessation
- 1998-06-29 AR ARP980103148A patent/AR015919A1/es not_active Application Discontinuation
- 1998-06-29 MY MYPI98002948A patent/MY129175A/en unknown
- 1998-06-30 TN TNTNSN98125A patent/TNSN98125A1/fr unknown
- 1998-06-30 PA PA19988454401A patent/PA8454401A1/es unknown
- 1998-06-30 DZ DZ980156A patent/DZ2546A1/fr active
- 1998-07-01 CO CO98037140A patent/CO4940402A1/es unknown
- 1998-07-01 HR HR980379A patent/HRP980379B1/xx not_active IP Right Cessation
1999
- 1999-11-23 IS IS5265A patent/IS5265A/is unknown
- 1999-11-23 BG BG103915A patent/BG103915A/xx unknown
- 1999-12-23 OA OA9900305A patent/OA11245A/en unknown
- 1999-12-28 NO NO996518A patent/NO996518L/no not_active Application Discontinuation
2006
- 2006-01-03 AR ARP060100016A patent/AR065827A2/es unknown

Also Published As

Publication number	Publication date
TR199903280T2 (xx)	2000-11-21
TNSN98125A1 (fr)	2005-03-15
KR100446366B1 (ko)	2004-09-01
CN1261793A (zh)	2000-08-02
JP2000514101A (ja)	2000-10-24
ID23503A (id)	2000-04-27
UY25067A1 (es)	2000-12-29
BR9810403A (pt)	2000-08-29
US6517866B1 (en)	2003-02-11
HRP980379A2 (en)	1999-04-30
AP9801281A0 (en)	1998-06-30
CA2290966C (fr)	2005-12-20
CO4940402A1 (es)	2000-07-24
EA199900964A1 (ru)	2000-08-28
HUP0002296A2 (hu)	2001-10-28
DZ2546A1 (fr)	2003-02-08
HK1026630A1 (en)	2000-12-22
IS5265A (is)	1999-11-23
CN1256085C (zh)	2006-05-17
MY129175A (en)	2007-03-30
AU739261B2 (en)	2001-10-11
KR100412327B1 (ko)	2003-12-31
AR065827A2 (es)	2009-07-08
AU7544998A (en)	1999-01-25
EP0999830A1 (fr)	2000-05-17
KR20040004367A (ko)	2004-01-13
IL133080A0 (en)	2001-03-19
NZ513456A (en)	2003-02-28
HRP980379B1 (en)	2003-04-30
NZ501251A (en)	2001-09-28
SK180499A3 (en)	2001-08-06
PE88699A1 (es)	1999-09-20
CA2290966A1 (fr)	1999-01-14
NO996518D0 (no)	1999-12-28
AP1526A (en)	2006-01-03
TWI241188B (en)	2005-10-11
PA8454401A1 (es)	2000-05-24
KR20010014043A (ko)	2001-02-26
NO996518L (no)	2000-02-29
HUP0002296A3 (en)	2001-11-28
IL152330A0 (en)	2003-05-29
AR015919A1 (es)	2001-05-30
PL337806A1 (en)	2000-09-11
EA002482B1 (ru)	2002-06-27
WO1999001121A1 (fr)	1999-01-14
OA11245A (en)	2003-07-23

Publication	Publication Date	Title
BG103915A (en)	2000-07-31	Sertraline salts and sertralin-containing batched forms with delayed release
MD1663B2 (en)	2001-05-31	Composition and methods for human sexual activity modulation and impotency treatment
BR9814389A (pt)	2000-10-10	Forma de dosagem farmacêutica revestida entérica, processo para a preparação da mesma, uso desta, pelota ou tablete encamado para a mesma, e, processos para melhorar a inibição da secreção de ácido gástrico, e para melhorar o efeito terapêutico no tratamento de distúrbios gastrointestinais associados com secreção de ácido em excesso
HUT54060A (en)	1991-01-28	Process for producing pharmaceutical compositions with antiviral or antibacterial effect
FI950319A0 (fi)	1995-01-25	Säädellyn vapautumisnopeuden omaava morfiinivalmiste
IL120317A (en)	2000-08-13	Ciprofloxacin-hydrocortisone suspension
MY129293A (en)	2007-03-30	The use of mmp-13 selective inhibitors for the treatment of osteoarthristis and other mmp-mediated disorders
ZA896150B (en)	1991-01-30	The use of alpha-amino boronic acid derivatives for the prophylaxis and treatment of virus diseases
PL310476A1 (en)	1995-12-11	Application of lamotrigin in treating neuro-aids diseases
PT777482E (pt)	2002-04-29	Composicao de combinacao para utilizacao em doencas imunologicas
GR3034040T3 (en)	2000-11-30	CoA-IT AND PAF INHIBITORS.
BG102556A (en)	1999-02-26	Orally applied pharmaceutical composition with modified release containing 5-asa, and a method for the treatment of intestinal diseases
NZ503169A (en)	2001-12-21	Synthesis of clasto-lactacystin beta-lactone whereupon the process relies upon a stereoselective addition of a formyl amide to an oxazoline
MY104006A (en)	1993-10-30	4-quinoline carboxylic acid derivatives useful for treating skin and muco-epithelial diseases.
MY118244A (en)	2004-09-30	Alfa-amino acid amides, preparation thereof and the therapeutical use thereof
EP0277740A3 (en)	1989-03-29	Aqueous film-forming compositions for controlling the release of active agents and process of making same
NO179245C (no)	1996-09-04	Arylalkylestere av 4,5-dihydroksy-9,10-dihydro-9,10-diokso-2-antracenkarboksylsyre med terapeutisk aktivitet
EP1016408A4 (fr)	2003-03-05	Inhibiteur de la production de chemokine c-c
EP0330218A3 (fr)	1992-01-02	Inhibiteurs de la lysyle oxydase
FI891324A0 (fi)	1989-03-21	1-metyyli-3,5,7-triatsa-1-atsoniatrisyklodekaaniyhdisteitä, menetelmä näiden yhdisteiden valmistamiseksi ja niiden käyttö mikro-organismien kontrolloimiseksi vesijärjestelmissä sekä niiden käyttö korroosionestoaineina
EP0348290A3 (fr)	1990-05-30	Monocytes tueurs activés : activité tumoricide et méthode pour leur contrôle
AU2489188A (en)	1989-04-18	In vitro method for the induction of the spermatozoal acrosome reaction and application of said method to the assessment of spermatozoa and the treatment of male-related infertility
MY106605A (en)	1995-06-30	Compositions for the treatment of leishmaniasis
DE69331237D1 (de)	2002-01-10	Antiatherosclerotische mittel
MD1296F1 (en)	1999-08-30	The Nicolau method of treatment of the lichen planus